146 related articles for article (PubMed ID: 38287743)
1. Genetic testing for familial melanoma.
Primiero CA; Maas EJ; Wallingford CK; Soyer HP; McInerney-Leo AM
Ital J Dermatol Venerol; 2024 Feb; 159(1):34-42. PubMed ID: 38287743
[TBL] [Abstract][Full Text] [Related]
2. Prognosis of CDKN2A germline mutation in patients with familial melanoma: a systematic review and meta-analysis.
Taibo A; Paradela S; Suanzes-Hernández J; Balboa-Barreiro V; Amado-Bouza J; Fonseca E
Melanoma Res; 2024 Feb; 34(1):9-15. PubMed ID: 37924530
[TBL] [Abstract][Full Text] [Related]
3. Immunophenotypic p14 and p16 correlations with CDKN2A mutations in primary multiple and familial melanoma: An observational study.
Boşoteanu LA; Gheorghe E; Aşchie M; Cozaru GC; Deacu M; Orășanu CI; Boşoteanu M
Medicine (Baltimore); 2023 Dec; 102(51):e36756. PubMed ID: 38134090
[TBL] [Abstract][Full Text] [Related]
4. Familial Melanoma: Diagnostic and Management Implications.
Rossi M; Pellegrini C; Cardelli L; Ciciarelli V; Di Nardo L; Fargnoli MC
Dermatol Pract Concept; 2019 Jan; 9(1):10-16. PubMed ID: 30775140
[TBL] [Abstract][Full Text] [Related]
5. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample.
Begg CB; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Mitra N; Busam K; From L; Berwick M;
J Natl Cancer Inst; 2005 Oct; 97(20):1507-15. PubMed ID: 16234564
[TBL] [Abstract][Full Text] [Related]
6. Geographical variation in the penetrance of CDKN2A mutations for melanoma.
Bishop DT; Demenais F; Goldstein AM; Bergman W; Bishop JN; Bressac-de Paillerets B; Chompret A; Ghiorzo P; Gruis N; Hansson J; Harland M; Hayward N; Holland EA; Mann GJ; Mantelli M; Nancarrow D; Platz A; Tucker MA;
J Natl Cancer Inst; 2002 Jun; 94(12):894-903. PubMed ID: 12072543
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
8. FRAMe: Familial Risk Assessment of Melanoma-a risk prediction tool to guide CDKN2A germline mutation testing in Australian familial melanoma.
Holland EA; Lo S; Kelly B; Schmid H; Cust AE; Palmer JM; Drummond M; Hayward NK; Pritchard AL; Mann GJ
Fam Cancer; 2021 Jul; 20(3):231-239. PubMed ID: 32989607
[TBL] [Abstract][Full Text] [Related]
9. Genetic counselling and high-penetrance susceptibility gene analysis reveal the novel CDKN2A p.D84V (c.251A>T) mutation in melanoma-prone families from Italy.
Borroni RG; Manganoni AM; Grassi S; Grasso M; Diegoli M; Giorgianni C; Favalli V; Pavoni L; Cespa M; Arbustini E
Melanoma Res; 2017 Apr; 27(2):97-103. PubMed ID: 28060055
[TBL] [Abstract][Full Text] [Related]
10. Selection criteria for genetic assessment of patients with familial melanoma.
Leachman SA; Carucci J; Kohlmann W; Banks KC; Asgari MM; Bergman W; Bianchi-Scarrà G; Brentnall T; Bressac-de Paillerets B; Bruno W; Curiel-Lewandrowski C; de Snoo FA; Debniak T; Demierre MF; Elder D; Goldstein AM; Grant-Kels J; Halpern AC; Ingvar C; Kefford RF; Lang J; MacKie RM; Mann GJ; Mueller K; Newton-Bishop J; Olsson H; Petersen GM; Puig S; Rigel D; Swetter SM; Tucker MA; Yakobson E; Zitelli JA; Tsao H
J Am Acad Dermatol; 2009 Oct; 61(4):677.e1-14. PubMed ID: 19751883
[TBL] [Abstract][Full Text] [Related]
11. Absence of germline CDKN2A mutation in Sicilian patients with familial malignant melanoma: Could it be a population-specific genetic signature?
Di Lorenzo S; Fanale D; Corradino B; Caló V; Rinaldi G; Bazan V; Giordano A; Cordova A; Russo A
Cancer Biol Ther; 2016; 17(1):83-90. PubMed ID: 26650572
[TBL] [Abstract][Full Text] [Related]
12.
Pissa M; Helkkula T; Appelqvist F; Silander G; Borg Å; Pettersson J; Lapins J; Nielsen K; Höiom V; Helgadottir H
Acta Oncol; 2021 Jul; 60(7):888-896. PubMed ID: 33945383
[No Abstract] [Full Text] [Related]
13. A Systematic Review on the Impact of Genetic Testing for Familial Melanoma I: Primary and Secondary Preventative Behaviours.
Primiero CA; Yanes T; Finnane A; Soyer HP; McInerney-Leo AM
Dermatology; 2021; 237(5):806-815. PubMed ID: 33588421
[TBL] [Abstract][Full Text] [Related]
14. Genetic test reporting of CDKN2A provides informational and motivational benefits for managing melanoma risk.
Aspinwall LG; Stump TK; Taber JM; Drummond DM; Kohlmann W; Champine M; Leachman SA
Transl Behav Med; 2018 Jan; 8(1):29-43. PubMed ID: 29385581
[TBL] [Abstract][Full Text] [Related]
15. Genetic Testing in Familial Melanoma : Epidemiologic/Genetic Assessment of Risks and Role of CDKN2A Analysis.
Hogg D; Liu L; Lassam N
Methods Mol Med; 2001; 61():109-22. PubMed ID: 22323255
[TBL] [Abstract][Full Text] [Related]
16. CDKN2A founder mutation in pancreatic ductal adenocarcinoma patients without cutaneous features of Familial Atypical Multiple Mole Melanoma (FAMMM) syndrome.
Cremin C; Howard S; Le L; Karsan A; Schaeffer DF; Renouf D; Schrader KA
Hered Cancer Clin Pract; 2018; 16():7. PubMed ID: 29541281
[TBL] [Abstract][Full Text] [Related]
17. Management of familial melanoma.
Bishop JN; Harland M; Randerson-Moor J; Bishop DT
Lancet Oncol; 2007 Jan; 8(1):46-54. PubMed ID: 17196510
[TBL] [Abstract][Full Text] [Related]
18. Unaffected family members report improvements in daily routine sun protection 2 years following melanoma genetic testing.
Aspinwall LG; Taber JM; Kohlmann W; Leaf SL; Leachman SA
Genet Med; 2014 Nov; 16(11):846-53. PubMed ID: 24763292
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
